by The global hepatology market size accounted for US$ 13.02 Bn in 2022 and is projected to reach around USD 40.22 Bn by 2032, growing at a CAGR of 11.94% from 2023 to 2032.
Key Takeaways:
- North America is expected to dominate the hepatology market during the forecast period.
- By treatment type, the antiviral drugs segment is expected to be the dominating segment throughout the forecast period.
- By disease type, the hepatitis segment is expected to be the leading segment of the market. On the other hand, the liver cancer segment will grow at a significant rate during the forecast period.
Report Summary
The global hepatology market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the hepatology market across the globe.
A comprehensive estimate on the hepatology market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of hepatology during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3186
Hepatology Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 14.57 Billion |
| Market Size by 2032 | USD 40.22 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 11.94% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 To 2032 |
| Segments Covered | By Treatment Type and By Disease Type |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized hepatology market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Compounding Pharmacy Market Size To Cross USD 28.19 Bn By 2032
Hepatology Market Players
The report includes the profiles of key hepatology market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- Astellas Pharma Inc.
- Merck & Co. Inc.
- Abbott Laboratories
- Bristol- Myers Squibb
- AbbVie Inc.
- Emergent BioSolutions Inc.
- F. Hoffmann- La Roche AG
- Eli Lilly and Company
- Viatris Inc.
- Gilead Sciences, Inc.
Market Segmentation
By Treatment Type
- Antiviral Drugs
- Vaccines
- Immunosuppressants
- Targeted Therapy
- Chemotherapy
- Corticosteroids
- Immunoglobulins
By Disease Type
- Hepatitis
- Liver Cancer
- Genetic Disorders
- Autoimmune Diseases
- Non- Alcoholic Fatty Liver Diseases
- Others
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Hepatology Market
5.1. COVID-19 Landscape: Hepatology Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Hepatology Market, By Treatment Type
8.1. Hepatology Market, by Treatment Type, 2023-2032
8.1.1. Antiviral Drugs
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Vaccines
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Immunosuppressants
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Targeted Therapy
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Chemotherapy
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Corticosteroids
8.1.6.1. Market Revenue and Forecast (2020-2032)
8.1.7. Immunoglobulins
8.1.7.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Hepatology Market, By Disease Type
9.1. Hepatology Market, by Disease Type, 2023-2032
9.1.1. Hepatitis
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Liver Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Genetic Disorders
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Autoimmune Diseases
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Non- Alcoholic Fatty Liver Diseases
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Hepatology Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.1.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
Chapter 11. Company Profiles
11.1. Astellas Pharma Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Merck & Co. Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbott Laboratories
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bristol- Myers Squibb
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. AbbVie Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Emergent BioSolutions Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. F. Hoffmann- La Roche AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Eli Lilly and Company
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Viatris Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Gilead Sciences, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
